RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy
Jonathan Sive(University College London Hospitals NHS Foundation Trust), Michael A. Chapman(Toronto Metropolitan University), Claire Roddie(Cancer Institute (WIA)), Nicholas Counsell(University College London), Mickey Koh(St George's Hospital), Paul D. Smith(Epworth Hospital), James D. Cavenagh(National Health Service), Gordon Cook(University of Leeds), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Mark Cook(Université Paris Cité), Matthew Streetly(King's College - North Carolina), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Toyin Adadayo(CRUK Lung Cancer Centre of Excellence), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Rakesh Popat(University College London Hospitals NHS Foundation Trust), Josephine Crowe(Royal United Hospital), John C. Ambrose(Jackson Laboratory), Stephen Schey(University College Hospital), Andres Virchis(The Royal Free Hospital), Michael F. Quinn(University of Ulster), Nivette Braganca(Cancer Research UK), Charles Crawley(Addenbrooke's Hospital), Shirley D’Sa(University College Hospital)
Cited by 0
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719